The Clinical Implications of the CHICAGO Study for the Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus

Trends in Cardiovascular Medicine

Volumn 19, Issue 3, 2009, Pages 94-99

  Polonsky, Tamar ^a   Mazzone, Theodore ^b   Davidson, Michael ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PIOGLITAZONE;

ADULT; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; FEMALE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTOLIC BLOOD PRESSURE;

CAROTID ARTERIES; CHICAGO; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TUNICA INTIMA;

EID: 68549085333     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2009.06.002     Document Type: Review

References (44)

1. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 Suppl 1 (2008) S12-S54
2. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
3. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
4. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 86 (2000) 19L-22L
5. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146 (1997) 483-494
6. Costa J., Borges M., David C., and Vaz C.A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006) 1115-1124
7. Davidson M., Meyer P.M., Haffner S., et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 117 (2008) 2123-2130
8. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
9. Erdmann E., Dormandy J.A., Charbonnel B., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 (2007) 1772-1780
10. Fleg J.L., Mete M., Howard B.V., et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 52 (2008) 2198-2205
11. Furberg C.D., Adams Jr. H.P., Applegate W.B., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90 (1994) 1679-1687
12. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
13. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
14. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
15. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
16. Hanefeld M., Marx N., Pfutzner A., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 49 (2007) 290-297
17. Hausenloy D.J., and Yellon D.M. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 84 (2008) 590-598
18. Hedblad B., Zambanini A., Nilsson P., et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 261 (2007) 293-305
19. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128 (1998) 262-269
20. Hodis H.N., Mack W.J., Zheng L., et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care 29 (2006) 1545-1553
21. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (2009) e391-e479
22. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
23. Koshiyama H., Shimono D., Kuwamura N., et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
24. Langenfeld M.R., Forst T., Hohberg C., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111 (2005) 2525-2531
25. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
26. Mazzone T. Reducing cardiovascular disease in patients with diabetes mellitus. Curr Opin Cardiol 2005 20 4 (2005) 245-249
27. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
28. Minamikawa J., Tanaka S., Yamauchi M., et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83 (1998) 1818-1820
29. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
30. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
31. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
32. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
33. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
34. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
35. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22
36. Rader D.J. Illuminating HDL-is it still a viable therapeutic target?. N Engl J Med 357 (2007) 2180-2183
37. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
38. Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
39. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
40. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
41. Smilde T.J., Van W.S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577-581
42. Stocker D.J., Taylor A.J., Langley R.W., et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 153 (2007) 445-446
43. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
44. Winkelmayer W.C., Setoguchi S., Levin R., and Solomon D.H. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 168 (2008) 2368-2375